PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP).
In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all patients were either undetectable or minimal, highlighting LP-310's potential to deliver localized therapeutic effects while minimizing systemic exposure. Additionally, all patients tolerated LP-310 without significant adverse reactions.
"The tolerability observed in this initial cohort is a promising indicator," noted Janet Okonski, Director of Clinical Operations at Lipella Pharmaceuticals. "Oral Lichen Planus severely affects patient quality of life, and an effective, well-tolerated treatment is desperately needed."
Following a successful internal safety evaluation of the first dose cohort, the trial has received approval to advance to the next stage of the trial, which will evaluate a higher dose of 0.5 mg of LP-310.
"We are proud of this milestone and are grateful to our investigators and study staff for their dedication and hard work," said Dr. Michael Chancellor, Chief Medical Officer of Lipella Pharmaceuticals.
Oral Lichen Planus (OLP) is a chronic inflammatory condition that affects the mucous membranes inside the mouth, which can cause pain and make eating, drinking and even speaking uncomfortable. Characterized by symptoms such as burning pain, white patches, swollen tissue, and open sores.
About the Study
The Oral Lichen Planus Clinical Trial is a multicenter study involving adult male and female subjects (18 years and older) with symptomatic OLP. This study will evaluate the safety, tolerability and efficacy of LP-10 at doses of 0.25 mg, 0.5 mg and 1.0 mg of tacrolimus across seven sites in the U.S.
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is focused on developing new drugs by reformulating active agents in existing generic drugs for new applications targeting diseases with significant unmet needs where no approved drug therapies currently exist.